Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease treatments, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will present on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.
Investors and interested parties can access a live audio webcast of the presentation through Soleno's website. The presentation will also be available for replay in the Investors section at www.soleno.life. This conference provides Soleno with an opportunity to showcase its progress in developing novel therapeutics for rare diseases to a global audience of healthcare industry professionals and investors.
Soleno Therapeutics (NASDAQ: SLNO), una compagnia biofarmaceutica in fase clinica focalizzata sui trattamenti per malattie rare, ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale Cantor 2024. La direzione dell'azienda presenterà martedì 17 settembre 2024, alle 8:00 ora orientale.
Gli investitori e le parti interessate possono accedere a un webcast audio dal vivo della presentazione tramite il sito web di Soleno. La presentazione sarà inoltre disponibile per il replay nella sezione Investitori su www.soleno.life. Questa conferenza offre a Soleno l'opportunità di mostrare i propri progressi nello sviluppo di nuove terapie per malattie rare a un pubblico globale di professionisti del settore sanitario e investitori.
Soleno Therapeutics (NASDAQ: SLNO), una empresa biofarmacéutica en etapa clínica enfocada en tratamientos para enfermedades raras, ha anunciado su participación en la Conferencia Global de Salud Cantor 2024. La dirección de la empresa hará una presentación el martes 17 de septiembre de 2024, a las 8:00 AM hora del Este.
Los inversores y partes interesadas pueden acceder a un webcast de audio en vivo de la presentación a través del sitio web de Soleno. La presentación también estará disponible para su reproducción en la sección de Inversores en www.soleno.life. Esta conferencia brinda a Soleno la oportunidad de mostrar sus avances en el desarrollo de nuevos tratamientos para enfermedades raras ante una audiencia global de profesionales del sector salud e inversores.
솔레노 테라퓨틱스 (NASDAQ: SLNO)는 희귀 질환 치료에 집중하는 임상 단계의 생물 의약품 회사로, 2024 캔토 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 17일 화요일, 동부 표준시 오전 8시에 발표할 예정입니다.
투자자 및 이해관계자들은 솔레노의 웹사이트를 통해 발표의 실시간 오디오 웹캐스트에 접근할 수 있습니다. 발표는 www.soleno.life의 투자자 섹션에서 다시 볼 수 있습니다. 이번 컨퍼런스는 솔레노가 희귀 질환을 위한 새로운 치료제 개발의 진행 상황을 글로벌 헬스케어 산업 전문가와 투자자들에게 보여줄 수 있는 기회를 제공합니다.
Soleno Therapeutics (NASDAQ: SLNO), une entreprise bio-pharmaceutique en phase clinique axée sur les traitements des maladies rares, a annoncé sa participation à la Conférence Mondiale de Santé Cantor 2024. La direction de l'entreprise présentera le mardi 17 septembre 2024, à 8h00, heure de l'Est.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire audio en direct de la présentation via le site web de Soleno. La présentation sera également disponible en rediffusion dans la section Investisseurs sur www.soleno.life. Cette conférence offre à Soleno l'opportunité de mettre en avant ses progrès dans le développement de nouveaux traitements pour les maladies rares devant un public mondial de professionnels de la santé et d'investisseurs.
Soleno Therapeutics (NASDAQ: SLNO), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Seltene Krankheitsbehandlungen konzentriert, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference angekündigt. Das Management des Unternehmens wird am Dienstag, den 17. September 2024, um 8:00 Uhr Eastern Time präsentieren.
Investoren und interessierte Parteien können über die Website von Soleno auf einen Live-Audio-Webcast der Präsentation zugreifen. Die Präsentation wird auch in der Investoren-Sektion unter www.soleno.life als Wiederholung verfügbar sein. Diese Konferenz bietet Soleno die Gelegenheit, den Fortschritt bei der Entwicklung neuartiger Therapeutika für seltene Krankheiten einem globalen Publikum aus Fachleuten der Gesundheitsbranche und Investoren zu präsentieren.
- None.
- None.
REDWOOD CITY, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will present at the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024, at 8:00 AM Eastern Time.
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When is Soleno Therapeutics (SLNO) presenting at the 2024 Cantor Global Healthcare Conference?
How can I access Soleno Therapeutics' (SLNO) presentation at the 2024 Cantor Global Healthcare Conference?
What is the focus of Soleno Therapeutics (SLNO) as a company?
Where is Soleno Therapeutics (SLNO) based?
